Save up -80% on Alirocumab
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Praluent
|$1,117.20||1 carton (2 pens) 75mg/ml|
|price without discount in nearest pharmacy. Price may vary.|
We offer free Alirocumab coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Alirocumab every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Alirocumab volume of distribution
Following IV administration, the volume of distribution was about 0.04 to 0.05 L/kg indicating that alirocumab is distributed primarily in the circulatory system. Metabolism: Specific metabolism studies were not conducted, because alirocumab is a protein.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Alirocumab
Alirocumab is a biopharmaceutical drug approved by the FDA in July 2015 as a second line treatment for high cholesterol for adults whose LDL-cholesterol (LDL-C) is not controlled by diet and statin treatment. It is a human monoclonal antibody administered by subcutaneous injection that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. PCSK9 inhibition facilitates more LDL-C clearance from the blood.
Alirocumab mechanism of action
Alirocumab is a fully human IgG1 monoclonal antibody that binds and inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), an enzyme found to have “gain of function” mutations in autosomal dominant hypercholesterolemia. PCSK9 is secreted by the liver and typically binds to the LDL receptors in serum and marks them for lysosomal degradation. In result, the LDL receptors are not able to recycle to the plasma membrane, reducing their binding to LDL-C and therefore reducing the clearance of LDL-C from plasma. Therefore by inhibiting PCSK9’s actions, alirocumab allows for more LDL-C reuptake by the liver and facilitates a higher rate of clearance. Lower LDL cholesterol concentrations are associated with a reduced risk of coronary heart disease.
Dosage forms of Alirocumab
|Praluent||75mg/ml||1 carton (2 pens)||$1,149|
|Praluent||75mg/ml||1 carton (2 syringes)||$1,149|
|Praluent||150mg/ml||1 carton (2 pens)||$1,149|
|Praluent||150mg/ml||1 carton (2 syringes)||$1,149|
Sanofi Aventis Canada Inc
Indication of Alirocumab
Alirocumab is indicated as an adjunct to diet and maximally tolerated statin therapy in adults who require additional LDL-cholesterol (LDL-C) lowering due to heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease.
Toxicity of Alirocumab
In epidemiological studies, mild-to-moderate nasopharyngitis, injection-site pain, arthralgia and back pain were reported in patients receiving alirocumab and other PCSK9 inhibitors. Hypersensitivity reactions (pruritus, rash, urticaria), including hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization, have been reported. In clinical settings, alirocumab is administered by subcutaneous injection. The pharmacokinetics of alirocumab after single SC administration of 75 mg into the abdomen, upper arm, or thigh were similar.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Alirocumab on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.